Evotec enters biology collaboration with Probiodrug

30-Nov-2012 - Germany

Evotec AG announced that it has entered into a collaboration with Probiodrug AG. Under the terms of the agreement, Evotec will setup and validate assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer's disease. Glutaminyl cyclase is a novel proprietary enzyme target discovered and validated by Probiodrug which plays a crucial role in the pathogenesis of Alzheimer's disease (AD) as well as potentially other diseases.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the pre-clinical and clinical development of QC inhibitors in Alzheimer's disease and other indications. This is a good example of how Evotec can support Biotech companies with their specific drug discovery needs.'

Hendrik Liebers, Chief Financial Officer of Probiodrug, added: 'The collaboration will allow us to focus on the further pre-clinical and clinical development of our programmes in neurodegeneration/AD. Evotec, with its proven track record, is ideally suited to accompany this process by running existing and developing new biological assays.'

https://www.bionity.com/en/news/140660/evotec-enters-biology-collaboration-with-probiodrug.html